SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Cytokine1 who wrote (2595)9/23/1997 4:45:00 PM
From: Boyce Burge   of 9719
 
Aurora!! I encourage the VD boarders to mull over Aurora Bioscences, ABSC, described below, from my post on the ABSC thread. Its a very short thread, but I think Aurora may be a major player before long.....

" Aurora is a VERY interesting co! And the Warner Lambert deal today should be a screaming buy signal..

After the hype, and then the deflation of stocks like Arqule and Tripos early this year, I'm reluctant to bite on
another high- throughput screening co -- but after looking into ABSC a little, I'm sharpening my canines
(bought a little yesterday at 13 1/2).

I've looked at some of R Tsien's papers on the jellyfish green protein and appliications, and I think this guy is
a genius. The Green Protein fluoresces by itself, just amino acids, without benefit of the typical hydrophobic
fluorophore. So it can be spliced to other proteins or co- expressed with a marker gene, and used to light up
cells based on their lineage or gene expression. But, with combinations of other fl. molecules (not necessarily
protein), it can also be used to detect shifts in ions, membrane potential, binding to a receptor, or almost
anything you care to target. The green protein has also been modified genetically so that different mutants
fluoresce at different wavelengths and assay builders have several "colors" to work with (I used to work in
this area a little).

Tsien & colaborators have found ways to get these naturally fl. proteins to report on membrane potential,
Ca++ flux, ion channels, etc. Now the chem. combinatorics companies, like Arqule, will have biologically
RELEVANT assays to run their millions of compounds against (Arqule and Allanex are collaborators).

The science is sound and so is the business plan... my guess is ABSC will be profitable next year. The
genomics revolution wont have any impact on the drug business unless there are better assays to allow rapid
analysis of these new targets. These fl. assays of Tsien's are able to report on metabolically interesting
events like ion shifts (relevant to cardio and blood pressure drugs, for instance) -- and without perturbing the
cell in unnatural ways.

I confess I dont know the people who are running the co, but they are making the right moves. Brought public
by A Brown and H&Q... INCY CEO Roy W is on the board. Deals with instrumentation cos for slick
miniaturization and robotics schemes....

It may take Wall Street a while to figure out how important this technology is, but I think we have a
mini-AFFX or INCY on our hands. Look for upgrades from other brokerages soon. "
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext